Consistent with the Core of our Leitbild and Code of Conduct, we act with integrity and are committed to conducting business in a lawful and ethical manner.
Boehringer Ingelheim Social Engagements Contributes to company commitment to impact 50 million people in vulnerable communities by 2030 through supporting social entrepreneurs and innovative solutions
FDA approves Ofev® as the first and only therapy in the U.S. to slow the rate of decline in pulmonary function in patients with systemic sclerosis-associated ILD
"You can work on initiatives that can improve treatment, provision, and early disease detection"", Michael Schmelmer, Member of the Board of Managing Directors